Wei Wei, Li Changling, Wang Yinye, Kritchevsky David
Department of Biochemical Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100083, China.
Res Commun Mol Pathol Pharmacol. 2006;119(1-6):67-75.
Monascus purpureus-fermented rice (MR), a preparation which has been shown to be hypolipidemic and antiatherogenic in rabbits and hamsters was fed to quail maintained on a high fat diet to determine if it could influence lipidemia and hepatic steatosis. MR was fed at two levels (0.8 or 1.6 g/kg/d), and compared with a lipoptropic preparation (dongbaogantai 0.6 g/kg/d) and an established hypolipidemic compound (lovastatin 6 mg/kg/d). All the test compounds lowered serum lipids and liver cholesterol levels. Dongbaogantai inhibited hepatic steatosis to the greatest extent (78%), lovastatin inhibited steatosis by 29% and the low and high doses of MR by 25 and 43%, respectively. These serum cholesterol lowering agents have been shown to reduce hepatic steatosis induced by dietary means.
紫红曲霉发酵米(MR),一种已被证明在兔子和仓鼠中具有降血脂和抗动脉粥样硬化作用的制剂,被喂给以高脂饮食喂养的鹌鹑,以确定它是否会影响血脂异常和肝脂肪变性。MR以两种剂量(0.8或1.6克/千克/天)喂食,并与一种促脂肝制剂(东宝肝泰0.6克/千克/天)和一种已确定的降血脂化合物(洛伐他汀6毫克/千克/天)进行比较。所有受试化合物均降低了血清脂质和肝脏胆固醇水平。东宝肝泰对肝脂肪变性的抑制作用最大(78%),洛伐他汀抑制脂肪变性29%,低剂量和高剂量的MR分别抑制25%和43%。这些血清胆固醇降低剂已被证明可减少饮食诱导的肝脂肪变性。